ICER Says CAR T Drug Overpriced Because Not One-Time Treatment

By Gabrielle Wanneh / April 16, 2021 at 1:21 PM
A newly approved CAR T drug for multiple myeloma is overpriced in part because, unlike other chimeric antigen receptor T-cell drugs, it might need to be administered more than once, according to the Institute for Clinical & Economic Review . FDA last month approved Abecma, a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for multiple myeloma. The makers of Abecma, Bristol Myers Squibb and bluebird bio, charge $419,000 per treatment. ICER suggests a price range of $192,000 to $265,000...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.